ATE325611T1 - Borsäuresalze und deren verwendung in der bereitstellung von medikamente für die thrombosebehandlung - Google Patents

Borsäuresalze und deren verwendung in der bereitstellung von medikamente für die thrombosebehandlung

Info

Publication number: ATE325611T1
Authority: AT; Austria
Prior art keywords: medications; provision; boric acid; acid salts; formula
Prior art date: 2002-09-09

Application number

AT03255629T

Other languages

English (en)

Inventor

David Jonathan Madge

Mark Dolman

Sophie Marie Combe-Marzelle

John Joseph Deadman

Anthony James Kennedy

Sanjay Kumar Kakkar

Original Assignee

Trigen Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-09

Filing date

2003-09-09

Publication date

2006-06-15

2002-09-09 Priority claimed from GB0220822A external-priority patent/GB0220822D0/en

2002-09-09 Priority claimed from GB0220764A external-priority patent/GB0220764D0/en

2003-04-04 Priority claimed from GB0307817A external-priority patent/GB0307817D0/en

2003-05-16 Priority claimed from GB0311237A external-priority patent/GB0311237D0/en

2003-07-04 Priority claimed from GB0315691A external-priority patent/GB0315691D0/en

2003-09-09 Application filed by Trigen Ltd filed Critical Trigen Ltd

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE325611T1 publication Critical patent/ATE325611T1/de

Links

208000007536 Thrombosis Diseases 0.000 title abstract 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
-1 boronate anions Chemical class 0.000 abstract 2
150000008064 anhydrides Chemical class 0.000 abstract 1
230000002785 anti-thrombosis Effects 0.000 abstract 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 abstract 1
125000005620 boronic acid group Chemical class 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT03255629T 2002-09-09 2003-09-09 Borsäuresalze und deren verwendung in der bereitstellung von medikamente für die thrombosebehandlung ATE325611T1 (de)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GB0220822A GB0220822D0 (en)	2002-09-09	2002-09-09	Boropeptides
GB0220764A GB0220764D0 (en)	2002-09-09	2002-09-09	Boropeptides
GB0307817A GB0307817D0 (en)	2003-04-04	2003-04-04	Boronic acid compounds
GB0311237A GB0311237D0 (en)	2003-05-16	2003-05-16	Boronic acid compounds
GB0315691A GB0315691D0 (en)	2003-07-04	2003-07-04	Boropeptides
US48578603P	2003-07-08	2003-07-08

Publications (1)

Publication Number	Publication Date
ATE325611T1 true ATE325611T1 (de)	2006-06-15

Family

ID=31721886

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT03255629T ATE325611T1 (de)	2002-09-09	2003-09-09	Borsäuresalze und deren verwendung in der bereitstellung von medikamente für die thrombosebehandlung
AT04076510T ATE376551T1 (de)	2002-09-09	2003-09-09	Peptidborsäuren und deren verwendung in der herstellung von salzen derselben
AT03255590T ATE324899T1 (de)	2002-09-09	2003-09-09	In parenteralen formulierungen für die selektive thrombininhibierung verwendbare borsäuresalze

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AT04076510T ATE376551T1 (de)	2002-09-09	2003-09-09	Peptidborsäuren und deren verwendung in der herstellung von salzen derselben
AT03255590T ATE324899T1 (de)	2002-09-09	2003-09-09	In parenteralen formulierungen für die selektive thrombininhibierung verwendbare borsäuresalze

Country Status (19)

Country	Link
EP (8)	EP1396270B1 (de)
JP (3)	JP2006503903A (de)
KR (2)	KR20050057295A (de)
CN (2)	CN100447151C (de)
AT (3)	ATE325611T1 (de)
AU (3)	AU2003263328A1 (de)
BR (1)	BR0314450A (de)
CA (3)	CA2536010A1 (de)
CY (1)	CY1105381T1 (de)
DE (3)	DE60305113T2 (de)
DK (2)	DK1400245T3 (de)
ES (2)	ES2263924T3 (de)
IL (1)	IL167294A (de)
MX (2)	MXPA05002661A (de)
NZ (2)	NZ539334A (de)
PL (2)	PL376439A1 (de)
PT (1)	PT1396270E (de)
SI (2)	SI1400245T1 (de)
WO (3)	WO2004022072A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0405267D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
GB0405280D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
GB0405272D0 (en) *	2004-03-09	2004-04-21	Trigen Ltd	Compounds
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006059082A1 (en) *	2004-11-30	2006-06-08	Trigen Limited	Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0515003D0 (en) *	2005-07-21	2005-08-31	Univ Aston	Medical devices and coatings therefor
US7261742B2 (en)	2005-10-13	2007-08-28	S.C. Johnson & Son, Inc.	Method of deodorizing a textile
BRPI0815613A2 (pt) *	2007-08-21	2015-03-24	Alza Corp	Composições lipossômicas para administração in vivo de compostos de ácido borônico.
BRPI0815713A2 (pt) *	2007-08-21	2015-02-10	Alza Corp	Formulações lipossômicas de compostos de ácido borônico.
US8389232B2 (en) *	2008-05-13	2013-03-05	The Regents Of The University Of California	Fluorescence detection of poison oak oil
BR122014008754A2 (pt)	2008-06-17	2015-11-03	Millennium Pharm Inc	processos para a geração de compostos de éster boronato e ditos compostos
MX2011005376A (es) *	2008-11-21	2011-10-19	Iroko Cardio Llc	Metodo para reducir trombocitopenia y mortalidad asociada a trombocitopenia.
WO2010096574A1 (en)	2009-02-20	2010-08-26	Lisanti Michael P	A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN101928329B (zh) *	2009-06-19	2013-07-17	北京大学	三肽硼酸(酯)类化合物、其制备方法和应用
US10085987B2 (en)	2012-01-27	2018-10-02	Thomas Jefferson University	MCT protein inhibitor-related prognostic and therapeutic methods
WO2014172627A1 (en)	2013-04-19	2014-10-23	Thomas Jefferson University	Caveolin-1 related methods for treating glioblastoma with temozolomide
CN107001391B (zh) *	2014-10-01	2020-11-27	默克专利股份公司	硼酸衍生物
EP3472151A4 (de)	2016-06-21	2020-03-04	Orion Ophthalmology LLC	Carbocyclische prolinamidderivate
KR102595723B1 (ko)	2016-06-21	2023-10-27	오리온 옵탈몰로지 엘엘씨	헤테로시클릭 프롤린아미드 유도체
CN109187155B (zh) *	2018-07-27	2021-08-13	临沂大学	一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) *	2019-08-23	2020-04-24	브릿지바이오테라퓨틱스(주)	팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
WO2022186265A1 (ja) *	2021-03-05	2022-09-09	Ａｇｃ株式会社	化合物、化合物の製造方法及び表面処理剤の製造方法
CN113121666B (zh) *	2021-03-10	2023-09-12	厦门大学	抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) *	2021-10-29	2023-04-18	重庆第二师范学院	一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5856695A (ja)	1981-09-28	1983-04-04	Nitto Boseki Co Ltd	新規なトロンビン測定用基質
US4499082A (en)	1983-12-05	1985-02-12	E. I. Du Pont De Nemours And Company	α-Aminoboronic acid peptides
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
EP0315574A3 (de)	1987-11-05	1990-08-22	Hoechst Aktiengesellschaft	Renin-Inhibitoren
US5574014A (en)	1988-04-28	1996-11-12	Thrombosis Research Institute	Inhibitors of trypsin-like enzymes
EP0341661A3 (de)	1988-05-11	1991-05-02	The Du Pont Merck Pharmaceutical Company	Alpha-Aminoborsäure-Derivate enthaltende Peptid-Mittel Zusammensetzungen
US5106948A (en)	1988-05-27	1992-04-21	Mao Foundation For Medical Education And Research	Cytotoxic boronic acid peptide analogs
US5288707A (en)	1990-08-13	1994-02-22	Sandoz Ltd.	Borolysine peptidomimetics
GB9017694D0 (en)	1990-08-13	1990-09-26	Sandoz Ltd	Improvements in or relating to organic chemistry
GB9024129D0 (en)	1990-11-06	1990-12-19	Thrombosis Research Trust	Inhibitors and substrates of thrombin
US5648338A (en)	1990-11-06	1997-07-15	Thrombosis Research Institute	Inhibitors and substrates of thrombin
DE69206795T2 (de)	1991-04-30	1996-09-05	Procter & Gamble	ARYLBORONSäURE ENTHALTENDE FLüSSIGWASCHMITTEL
GB9224702D0 (en)	1992-11-25	1993-01-13	Thrombosis Res Inst	Boronic ester synthesis
FR2701951B1 (fr) *	1993-02-24	1995-06-09	Adir	Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ES2101516T3 (es)	1993-03-03	1997-07-01	Ciba Geigy Ag	Derivados peptidos de acido boronico que tienen actividad inhibidora de proteasas.
AU6448794A (en) *	1993-03-24	1994-10-11	Du Pont Merck Pharmaceutical Company, The	Boronic acid and ester inhibitors of thrombin
US5384410A (en) *	1993-03-24	1995-01-24	The Du Pont Merck Pharmaceutical Company	Removal of boronic acid protecting groups by transesterification
US5563127A (en)	1993-03-24	1996-10-08	The Dupont Merck Pharmaceutical Company	Boronic acid and ester inhibitors of thrombin
US5658885A (en)	1993-04-27	1997-08-19	The Dupont Merck Pharmaceutical Company	Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL109319A0 (en)	1993-04-27	1994-07-31	Du Pont Merck Pharma	Amidino and guanidino substituted boronic acid compounds
SE9900043D0 (sv)	1999-01-11	1999-01-11	Astra Ab	New use
US5681978A (en) *	1993-07-07	1997-10-28	Washington State University Research Foundation	Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111176A0 (en) *	1993-10-07	1994-12-29	Du Pont Merck Pharma	Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
CA2174311A1 (en) *	1993-10-07	1995-04-13	Gregory James Pacofsky	Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
US5462964A (en) *	1993-10-20	1995-10-31	The Du Pont Merck Pharmaceutical Company	Dipeptide boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en)	1993-10-07	1994-12-29	Du Pont Merck Pharma	Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5431842A (en)	1993-11-05	1995-07-11	The Procter & Gamble Company	Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en)	1994-01-26	1994-03-23	Sandoz Ltd	Organic compounds
FR2721611B1 (fr)	1994-06-22	1996-09-27	Adir	Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) *	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
JPH10511957A (ja)	1995-01-05	1998-11-17	ザボードオブリージェンツオブザユニヴァーシティオブミシガン	表面改質ナノ微粒子並びにその製造及び使用方法
GB9502985D0 (en)	1995-02-16	1995-04-05	Thrombosis Res Inst	Enzyme inhibitors
GB9515489D0 (en)	1995-07-28	1995-09-27	Sandoz Ltd	Organic compounds
GB9613718D0 (en) *	1996-06-29	1996-08-28	Thrombosis Res Inst	Thrombin inhibitors
GB9724786D0 (en) *	1997-11-25	1998-01-21	Danbiosyst Uk	Oral delivery system
CA2376965A1 (en)	1999-07-07	2001-01-11	Timothy Patrick Forsyth	Peptide boronic acid inhibitors of hepatitis c virus protease
SE9904483D0 (sv)	1999-12-08	1999-12-08	Astra Ab	New use
US6462021B1 (en)	2000-11-06	2002-10-08	Astrazeneca Ab	Use of low molecular weight thrombin inhibitor
ES2571219T3 (es) *	2001-01-25	2024-09-23	The United States Of America Represented By The Sec Dep Of Health And Human Services	Formulación de compuestos de ácido borónico
DE10133786A1 (de)	2001-07-16	2003-02-06	Boehringer Ingelheim Pharma	Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

2003
- 2003-09-09 KR KR1020057004077A patent/KR20050057295A/ko not_active Ceased
- 2003-09-09 CA CA002536010A patent/CA2536010A1/en not_active Abandoned
- 2003-09-09 DE DE60305113T patent/DE60305113T2/de not_active Expired - Lifetime
- 2003-09-09 CA CA002535788A patent/CA2535788A1/en not_active Abandoned
- 2003-09-09 WO PCT/GB2003/003897 patent/WO2004022072A1/en not_active Ceased
- 2003-09-09 AT AT03255629T patent/ATE325611T1/de not_active IP Right Cessation
- 2003-09-09 SI SI200330345T patent/SI1400245T1/sl unknown
- 2003-09-09 CN CNB038213907A patent/CN100447151C/zh not_active Expired - Fee Related
- 2003-09-09 DK DK03255590T patent/DK1400245T3/da active
- 2003-09-09 JP JP2004569794A patent/JP2006503903A/ja active Pending
- 2003-09-09 PL PL03376439A patent/PL376439A1/xx unknown
- 2003-09-09 JP JP2004569793A patent/JP2006509034A/ja active Pending
- 2003-09-09 MX MXPA05002661A patent/MXPA05002661A/es active IP Right Grant
- 2003-09-09 EP EP03255629A patent/EP1396270B1/de not_active Expired - Lifetime
- 2003-09-09 EP EP04076521A patent/EP1466917A1/de not_active Withdrawn
- 2003-09-09 AU AU2003263328A patent/AU2003263328A1/en not_active Abandoned
- 2003-09-09 ES ES03255629T patent/ES2263924T3/es not_active Expired - Lifetime
- 2003-09-09 AU AU2003263343A patent/AU2003263343A1/en not_active Abandoned
- 2003-09-09 SI SI200330344T patent/SI1396270T1/sl unknown
- 2003-09-09 JP JP2004569795A patent/JP2006511593A/ja active Pending
- 2003-09-09 PL PL376535A patent/PL376535A1/pl unknown
- 2003-09-09 NZ NZ539334A patent/NZ539334A/en not_active IP Right Cessation
- 2003-09-09 ES ES03255590T patent/ES2264515T3/es not_active Expired - Lifetime
- 2003-09-09 EP EP03255604A patent/EP1396269A1/de not_active Withdrawn
- 2003-09-09 CN CNB038214032A patent/CN100553639C/zh not_active Expired - Fee Related
- 2003-09-09 DE DE60304956T patent/DE60304956T2/de not_active Expired - Lifetime
- 2003-09-09 DK DK03255629T patent/DK1396270T3/da active
- 2003-09-09 WO PCT/GB2003/003887 patent/WO2004022071A1/en not_active Ceased
- 2003-09-09 EP EP06113409A patent/EP1695711A3/de not_active Withdrawn
- 2003-09-09 BR BR0314450-0A patent/BR0314450A/pt not_active IP Right Cessation
- 2003-09-09 EP EP04076548A patent/EP1561466A3/de not_active Withdrawn
- 2003-09-09 KR KR1020057004076A patent/KR20050057294A/ko not_active Ceased
- 2003-09-09 DE DE60317039T patent/DE60317039T2/de not_active Expired - Lifetime
- 2003-09-09 AT AT04076510T patent/ATE376551T1/de not_active IP Right Cessation
- 2003-09-09 MX MXPA05002662A patent/MXPA05002662A/es not_active Application Discontinuation
- 2003-09-09 AT AT03255590T patent/ATE324899T1/de not_active IP Right Cessation
- 2003-09-09 PT PT03255629T patent/PT1396270E/pt unknown
- 2003-09-09 EP EP06113648A patent/EP1695712A3/de not_active Withdrawn
- 2003-09-09 WO PCT/GB2003/003883 patent/WO2004022070A1/en not_active Ceased
- 2003-09-09 EP EP04076510A patent/EP1466916B1/de not_active Expired - Lifetime
- 2003-09-09 NZ NZ539333A patent/NZ539333A/en unknown
- 2003-09-09 CA CA002535792A patent/CA2535792A1/en not_active Abandoned
- 2003-09-09 EP EP03255590A patent/EP1400245B1/de not_active Expired - Lifetime
- 2003-09-09 AU AU2003263333A patent/AU2003263333A1/en not_active Abandoned
2005
- 2005-03-07 IL IL167294A patent/IL167294A/en not_active IP Right Cessation
2006
- 2006-07-03 CY CY20061100903T patent/CY1105381T1/el unknown

Also Published As

Publication number	Publication date
WO2004022071A1 (en)	2004-03-18
DK1400245T3 (da)	2006-08-28
WO2004022072A1 (en)	2004-03-18
DK1396270T3 (da)	2006-08-28
CY1105381T1 (el)	2010-07-28
CN1681517A (zh)	2005-10-12
BR0314450A (pt)	2005-07-26
EP1396270B1 (de)	2006-05-10
EP1396270A1 (de)	2004-03-10
MXPA05002661A (es)	2005-08-19
IL167294A (en)	2008-11-03
EP1561466A2 (de)	2005-08-10
AU2003263333A1 (en)	2004-03-29
NZ539334A (en)	2007-11-30
CA2536010A1 (en)	2004-03-18
DE60305113D1 (de)	2006-06-14
EP1396269A1 (de)	2004-03-10
DE60317039T2 (de)	2008-07-31
ES2264515T3 (es)	2007-01-01
AU2003263343A1 (en)	2004-03-29
EP1695712A2 (de)	2006-08-30
DE60304956D1 (de)	2006-06-08
NZ539333A (en)	2007-02-23
SI1396270T1 (sl)	2006-10-31
JP2006511593A (ja)	2006-04-06
MXPA05002662A (es)	2005-09-20
CN1684693A (zh)	2005-10-19
ATE376551T1 (de)	2007-11-15
PL376439A1 (en)	2005-12-27
ES2263924T3 (es)	2006-12-16
KR20050057295A (ko)	2005-06-16
JP2006509034A (ja)	2006-03-16
EP1466916A1 (de)	2004-10-13
PT1396270E (pt)	2006-08-31
EP1466917A1 (de)	2004-10-13
CN100553639C (zh)	2009-10-28
DE60304956T2 (de)	2007-01-25
EP1400245B1 (de)	2006-05-03
HK1063154A1 (en)	2004-12-17
WO2004022070A1 (en)	2004-03-18
CN100447151C (zh)	2008-12-31
SI1400245T1 (sl)	2006-10-31
PL376535A1 (pl)	2006-01-09
EP1561466A3 (de)	2006-08-23
EP1695712A3 (de)	2008-01-09
EP1695711A2 (de)	2006-08-30
EP1695711A3 (de)	2008-01-02
EP1466916B1 (de)	2007-10-24
DE60317039D1 (de)	2007-12-06
EP1400245A1 (de)	2004-03-24
JP2006503903A (ja)	2006-02-02
CA2535792A1 (en)	2004-03-18
CA2535788A1 (en)	2004-03-18
DE60305113T2 (de)	2006-12-07
KR20050057294A (ko)	2005-06-16
ATE324899T1 (de)	2006-06-15
AU2003263328A1 (en)	2004-03-29

Legal Events

Date

Code

Title

Description

2007-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1396270

Country of ref document: EP

2011-06-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE325611T1 (de)	2006-06-15	Borsäuresalze und deren verwendung in der bereitstellung von medikamente für die thrombosebehandlung
MA23170A1 (fr)	1994-12-31	Procede de preparation d'un nouveau compose .
TR199500826A2 (tr)	1996-06-21	Multipl ünite tablet doz formu 2.
CA2494601A1 (en)	2004-03-25	N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
ITRM910730A1 (it)	1993-03-30	Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
SE0102057D0 (sv)	2001-06-08	New Salts I
SE0102058D0 (sv)	2001-06-08	New Salts II
ATE241640T1 (de)	2003-06-15	Fusidinsäure-derivate
TNSN00196A1 (fr)	2005-11-10	Agents therapeutiques